Company Overview of Karyon-CTT Ltd.
Karyon, Ltd. develops peptides into carriers for use in cancer diagnostics, imaging, and therapy. It offers Karyon Targeting Unit, a synthetic peptide that targets specific tumor tissue. The company engages in the areas of cancer biology and cell growth regulation, angiogenesis, biochemistry, peptide chemistry, organic syntheses and immunohistochemistry. Karyon, Ltd. was founded in 2001 and is based in Helsinki, Finland. As of May 6, 2008, Karyon Ltd. operates as a subsidiary of Isogenica Limited.
Founded in 2001
358 9319 36400
358 9319 36415
Key Executives for Karyon-CTT Ltd.
Similar Private Companies By Industry
|Arctic Diagnostics Oy||Europe|
|Bioxid Ltd Oy||Europe|
|Blueprint Genetics Oy||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Karyon-CTT Ltd., please visit www.karyon.fi. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.